{"id":"https://openalex.org/A5110051750","orcid":"https://orcid.org/0009-0006-4504-7760","observed_orcids":["https://orcid.org/0009-0006-4504-7760"],"display_name":"Jim Griffith","raw_author_names":["Jim Griffith"],"full_name":"Jim Griffith","works_count":25,"cited_by_count":174,"summary_stats":{"2yr_mean_citedness":2.875,"h_index":2,"i10_index":2},"ids":{"openalex":"https://openalex.org/A5110051750","orcid":"https://orcid.org/0009-0006-4504-7760","observed_orcids":["https://orcid.org/0009-0006-4504-7760"]},"affiliations":[{"institution":{"id":"https://openalex.org/I61970326","ror":"https://ror.org/00anb1726","display_name":"Vertex Pharmaceuticals (United States)","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]},"years":[1994]}],"last_known_institutions":null,"topics":[{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","count":24,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","count":24,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","count":12,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","count":10,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","count":2,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"topic_share":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","value":0.0003795,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","value":0.0001819,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","value":0.00016,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","value":4.21e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12620","display_name":"Signaling Pathways in Disease","value":1.36e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"x_concepts":[{"id":"2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","score":0.8633841872215271},{"id":"102744134","wikidata":"https://www.wikidata.org/wiki/Q22280388","display_name":"Homologous recombination","score":0.7846029996871948},{"id":"182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","score":0.5534999966621399},{"id":"64894306","wikidata":"https://www.wikidata.org/wiki/Q849622","display_name":"Homologous chromosome","score":0.516700029373169},{"id":"552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","score":0.322299987077713}],"counts_by_year":[{"year":1994,"works_count":1,"oa_works_count":0,"cited_by_count":0},{"year":2013,"works_count":0,"oa_works_count":0,"cited_by_count":2},{"year":2015,"works_count":0,"oa_works_count":0,"cited_by_count":3},{"year":2016,"works_count":0,"oa_works_count":0,"cited_by_count":1},{"year":2018,"works_count":0,"oa_works_count":0,"cited_by_count":1},{"year":2022,"works_count":0,"oa_works_count":0,"cited_by_count":1},{"year":2024,"works_count":14,"oa_works_count":14,"cited_by_count":1},{"year":2025,"works_count":0,"oa_works_count":0,"cited_by_count":26},{"year":2026,"works_count":10,"oa_works_count":10,"cited_by_count":42}],"display_name_alternatives":["Jim Griffith"],"block_key":"j griffith","works_api_url":"https://api.openalex.org/works?filter=author.id:A5110051750","updated_date":"2026-11-01T11:00:13","created_date":"2016-06-24T00:00:00"}